Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients

Comella, Pasquale; Frasci, G.; Carnicelli, Pietro; Massidda, B.; Buzzi, Franco; Filippelli, Gianfranco; Maiorino, Luigi; Guida, Michele; Panza, N.; Mancarella, S.; Cioffi, R

doi:10.1038/sj.bjc.6602011

Cited by 62 publications

(50 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reasons for exclusion were not stated in eight studies [30,31,40,42,43,48,57,64], whereas we were unable to assess if any exclusion criteria were applied in a trial published in Chinese only [46]. Response was assessed according to the World Health Organization standard criteria [72] in 19 trials [22,23,25,29,32,34,35,39,44,45,47,49,50,52,53,59,62,65,68], according to the Southwest Oncology Group guidelines [73] in two studies [21,24], and according to the Response Evaluation Criteria in Solid Tumors [74] in four trials [60,61,66,67].…”

Section: Patient Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Grossi¹,

Aita²,

Defferrari³

et al. 2009

The Oncologist

View full text Add to dashboard Cite

Background. The therapeutic equivalence of different third-generation agents in the first-line treatment of advanced non-small cell lung cancer (NSCLC) has long been accepted, although recent studies seem to suggest some superiority of gemcitabine-or docetaxel-containing regimens over other third-generation doublets.Objective. To assess the relative impact of different third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer by considering both response and progressive disease (PD) rates as outcome measures.Methods. Published and unpublished data were collected from randomized trials comparing a gemcitabine-, docetaxel-, vinorelbine-or paclitaxel-containing regimen with one or more gemcitabine-, docetaxel-, vinorelbine-or paclitaxel-free combinations. For

show abstract

Section: Patient Characteristicsmentioning

confidence: 99%

“…Among the remaining 45 trials [21-25, 29 -68], ineligible treatment arms-that is, triplets [30,63], single-agent therapies [44], platinum combinations with irinotecan or first-and second-generation drugs [36,38], or sequential treatment arms [39]-were excluded from the analysis.…”

Section: Identification Of Trialsmentioning

confidence: 99%

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Grossi¹,

Aita²,

Defferrari³

et al. 2009

The Oncologist

View full text Add to dashboard Cite

show abstract

“…A limitation of this comparison is the relatively low number of patients receiving various treatment regimens based on carboplatin (n = 33). Thirdly, the analysis showed the significant influence of the performance status and the age of patients on their overall survival, which was also observed in the clinical studies addressed for the patients in older age groups [22,23]. Our study also has a few potential drawbacks.…”

Section: Discussionmentioning

confidence: 80%

The results of first line systemic therapy of NSCLC in clinical practice

Adamowicz¹

2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Introduction. Lung cancer is the most common cancer in the world. Every year, there are over 1.4 million new cases and about 1.3 million deaths due to lung cancer. Data on the results of palliative treatment of patients with non-small cell lung cancer in Poland are scarce. Methods. The results of first-line palliative chemotherapy in 204 lung cancer patients treated in the period 2011-2014 in two cancer centres were analysed. Results. The mean age of the study group was 63.4 ± 8.3 years; 155 patients received chemotherapy with cisplatin, 33 -schemes containing carboplatin, 8 -inhibitors of EGFR tyrosine kinase, 8 -vinorelbine or gemcitabine monotherapy. Complete regression was observed in 2 patients, partial response -in 52 patients (25%), stable disease in 92 (45%) and 58 (28%) patients had progression. Median survival for the entire group of patients was 12 months. Multidrug chemotherapy with cisplatin compared with chemotherapy involving carboplatin monotherapy was associated with increased toxicity in total (p = 0.04). An increased toxicity concerned only to haematological complications and renal insufficiency expressed by the level of creatinine in blood serum. There was no apparent effect of chemotherapy on the overall quality of life. Conclusions. The results of palliative treatment of non-small cell lung cancer in daily practice are comparable to those obtained in prospective clinical trials despite having a different population of treated patients. The use of palliative chemotherapy had no significant effect on quality of life. NOWOTWORY J Oncol 2017; 67, 1: 24-33

show abstract

“…Comella and colleagues evaluated paclitaxel and gemcitabine in two randomized phase II studies [50,51]. Doublet treatment comprising paclitaxelgemcitabine or gemcitabine-vinorelbine was associated with a significantly longer OS time compared with paclitaxel or gemcitabine monotherapy (HR, 0.76; 95% CI, 0.59 -0.99), without an greater toxicity [51].…”

Section: First-line Therapymentioning

confidence: 99%

The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer

Ramalingam

Khuri

2009

The Oncologist

View full text Add to dashboard Cite

The treatment of older patients with advanced nonsmall cell lung cancer (NSCLC) represents a considerable challenge for physicians. A patient's suitability for chemotherapy is frequently based solely on chronologic age; as a consequence, older patients with NSCLC are less likely to receive standard chemotherapy than younger patients. Although age-related factors, such as comorbid illness, should be taken into consideration when assessing a patient's suitability for treatment, fit and functionally independent older patients should be considered candidates for standard chemotherapy. The taxanes are widely used in the treatment of advancedstage NSCLC and are well tolerated in older patients. The efficacy of both paclitaxel and docetaxel has been studied in older patients and appears to be comparable with that seen in younger patients either as monotherapy or in combination with a platinum compound as first-line therapy. In addition to the available evidence, prospective evaluation of novel agents in elderlyspecific or -enriched studies is necessary to guide the treatment of older patients with NSCLC. The Oncologist

show abstract

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients

Cited by 62 publications

References 34 publications

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

The results of first line systemic therapy of NSCLC in clinical practice

The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About